Delcath Systems Inc
Company Profile
Business description
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Contact
566 Queensbury Avenue
QueensburyNY12804
USAT: +1 212 489-2100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
76
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
stocks
Undervalued ASX retailer benefiting from rebound in spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.80 | 7.50 | -0.08% |
| CAC 40 | 8,136.87 | 68.25 | 0.85% |
| DAX 40 | 24,259.67 | 73.18 | 0.30% |
| Dow JONES (US) | 48,409.77 | 48.28 | -0.10% |
| FTSE 100 | 9,767.79 | 118.76 | 1.23% |
| HKSE | 25,628.88 | 347.91 | -1.34% |
| NASDAQ | 23,141.02 | 54.15 | -0.23% |
| Nikkei 225 | 50,168.11 | 668.44 | -1.31% |
| NZX 50 Index | 13,408.14 | 1.23 | 0.01% |
| S&P 500 | 6,824.79 | 2.62 | -0.04% |
| S&P/ASX 200 | 8,635.00 | 8.90 | -0.10% |
| SSE Composite Index | 3,867.92 | 21.42 | -0.55% |